Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study
Behçet's disease (BD) is a chronic multisystem inflammatory disorder associated to uveitis that may represent a serious sight-threatening condition. The purpose of the present study is to assess the effectiveness of adalimumab as new strategic therapeutic approach in patients affected by severe...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental rheumatology 2014-07, Vol.32 (4 Suppl 84), p.S58-S62 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S62 |
|---|---|
| container_issue | 4 Suppl 84 |
| container_start_page | S58 |
| container_title | Clinical and experimental rheumatology |
| container_volume | 32 |
| creator | Interlandi, Emanuela Leccese, Pietro Olivieri, Ignazio Latanza, Loredana |
| description | Behçet's disease (BD) is a chronic multisystem inflammatory disorder associated to uveitis that may represent a serious sight-threatening condition. The purpose of the present study is to assess the effectiveness of adalimumab as new strategic therapeutic approach in patients affected by severe Behçet's uveitis.
Clinical data from twelve selected patients (22 eyes) were retrospectively analysed. All patients received 40 mg of adalimumab subcutaneously, once every 2 weeks, in addition to traditional immunosuppressive on-going therapy and eight of them were switched to adalimumab after failure of infliximab therapy. Primary outcome measures included ocular inflammatory activity, frequency of uveitis attacks and steroid-sparing effect. Secondary outcomes were changes of best-corrected visual acuity (BCVA), impact on traditional immunosuppressive therapy and occurrence of adalimumab-related side effects.
Mean age of patients (11 males and 1 female) at the onset of disease was 24.34 years (±8.62 SD). Ocular involvement resulted bilateral in 83% of cases and mainly consisted in panuveitis (68% of eyes). After mean follow-up of 21 months (±9.63 SD) all patients but one (92%) achieved uveitis remission with BCVA improvement at least in one eye. Average uveitis attacks decreased from 2 to 0,42 during adalimumab (p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1567050590</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1567050590</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-7feb94a61c846ebb907a679d06f88cd258aac9b9bb934bee6a8fc57fb356c10c3</originalsourceid><addsrcrecordid>eNo1kMtKxDAYhbNQnHH0FSQ73RTStEkbd-PgDQbcKLgrSfpHK0lTcxmZJ_JBfDELjquzOB8fnHOElqQStGgZf12g0xg_CKGc8eYELSgjhFFaL1G37qUdXHZSYeMDTgFkcjAm7A2OsIMA-Abef74hXUacdzCkIV5jiQOk4OMEOg07wNaPb0WC4GaJtf6ryBOOKff7M3RspI1wfsgVerm7fd48FNun-8fNeltMtCxT0RhQopa81G3NQSlBGskb0RNu2lb3lLVSaqHE3FS1AuCyNZo1RlWM65LoaoWu_rxT8J8ZYurcEDVYK0fwOXblPJwwwgSZ0YsDmpWDvpvC4GTYd_-nVL8Uhl9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1567050590</pqid></control><display><type>article</type><title>Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Interlandi, Emanuela ; Leccese, Pietro ; Olivieri, Ignazio ; Latanza, Loredana</creator><creatorcontrib>Interlandi, Emanuela ; Leccese, Pietro ; Olivieri, Ignazio ; Latanza, Loredana</creatorcontrib><description>Behçet's disease (BD) is a chronic multisystem inflammatory disorder associated to uveitis that may represent a serious sight-threatening condition. The purpose of the present study is to assess the effectiveness of adalimumab as new strategic therapeutic approach in patients affected by severe Behçet's uveitis.
Clinical data from twelve selected patients (22 eyes) were retrospectively analysed. All patients received 40 mg of adalimumab subcutaneously, once every 2 weeks, in addition to traditional immunosuppressive on-going therapy and eight of them were switched to adalimumab after failure of infliximab therapy. Primary outcome measures included ocular inflammatory activity, frequency of uveitis attacks and steroid-sparing effect. Secondary outcomes were changes of best-corrected visual acuity (BCVA), impact on traditional immunosuppressive therapy and occurrence of adalimumab-related side effects.
Mean age of patients (11 males and 1 female) at the onset of disease was 24.34 years (±8.62 SD). Ocular involvement resulted bilateral in 83% of cases and mainly consisted in panuveitis (68% of eyes). After mean follow-up of 21 months (±9.63 SD) all patients but one (92%) achieved uveitis remission with BCVA improvement at least in one eye. Average uveitis attacks decreased from 2 to 0,42 during adalimumab (p<0.001) and daily-steroid dose was tapered in all adalimumab responders up to suspension in seven of them. No patient developed related side effects during adalimumab administration.
Our results demonstrate that adalimumab is a very effective and safe option for treatment of patients with severe and resistant Behçet's uveitis, providing an appropriate and long-term control of ocular inflammation.</description><identifier>ISSN: 0392-856X</identifier><identifier>PMID: 25005224</identifier><language>eng</language><publisher>Italy</publisher><subject>Adalimumab ; Adolescent ; Adult ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Behcet Syndrome - complications ; Behcet Syndrome - drug therapy ; Child ; Female ; Follow-Up Studies ; Humans ; Male ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome ; Uveitis - drug therapy ; Uveitis - etiology ; Young Adult</subject><ispartof>Clinical and experimental rheumatology, 2014-07, Vol.32 (4 Suppl 84), p.S58-S62</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25005224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Interlandi, Emanuela</creatorcontrib><creatorcontrib>Leccese, Pietro</creatorcontrib><creatorcontrib>Olivieri, Ignazio</creatorcontrib><creatorcontrib>Latanza, Loredana</creatorcontrib><title>Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>Behçet's disease (BD) is a chronic multisystem inflammatory disorder associated to uveitis that may represent a serious sight-threatening condition. The purpose of the present study is to assess the effectiveness of adalimumab as new strategic therapeutic approach in patients affected by severe Behçet's uveitis.
Clinical data from twelve selected patients (22 eyes) were retrospectively analysed. All patients received 40 mg of adalimumab subcutaneously, once every 2 weeks, in addition to traditional immunosuppressive on-going therapy and eight of them were switched to adalimumab after failure of infliximab therapy. Primary outcome measures included ocular inflammatory activity, frequency of uveitis attacks and steroid-sparing effect. Secondary outcomes were changes of best-corrected visual acuity (BCVA), impact on traditional immunosuppressive therapy and occurrence of adalimumab-related side effects.
Mean age of patients (11 males and 1 female) at the onset of disease was 24.34 years (±8.62 SD). Ocular involvement resulted bilateral in 83% of cases and mainly consisted in panuveitis (68% of eyes). After mean follow-up of 21 months (±9.63 SD) all patients but one (92%) achieved uveitis remission with BCVA improvement at least in one eye. Average uveitis attacks decreased from 2 to 0,42 during adalimumab (p<0.001) and daily-steroid dose was tapered in all adalimumab responders up to suspension in seven of them. No patient developed related side effects during adalimumab administration.
Our results demonstrate that adalimumab is a very effective and safe option for treatment of patients with severe and resistant Behçet's uveitis, providing an appropriate and long-term control of ocular inflammation.</description><subject>Adalimumab</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Behcet Syndrome - complications</subject><subject>Behcet Syndrome - drug therapy</subject><subject>Child</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Uveitis - drug therapy</subject><subject>Uveitis - etiology</subject><subject>Young Adult</subject><issn>0392-856X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtKxDAYhbNQnHH0FSQ73RTStEkbd-PgDQbcKLgrSfpHK0lTcxmZJ_JBfDELjquzOB8fnHOElqQStGgZf12g0xg_CKGc8eYELSgjhFFaL1G37qUdXHZSYeMDTgFkcjAm7A2OsIMA-Abef74hXUacdzCkIV5jiQOk4OMEOg07wNaPb0WC4GaJtf6ryBOOKff7M3RspI1wfsgVerm7fd48FNun-8fNeltMtCxT0RhQopa81G3NQSlBGskb0RNu2lb3lLVSaqHE3FS1AuCyNZo1RlWM65LoaoWu_rxT8J8ZYurcEDVYK0fwOXblPJwwwgSZ0YsDmpWDvpvC4GTYd_-nVL8Uhl9w</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Interlandi, Emanuela</creator><creator>Leccese, Pietro</creator><creator>Olivieri, Ignazio</creator><creator>Latanza, Loredana</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140701</creationdate><title>Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study</title><author>Interlandi, Emanuela ; Leccese, Pietro ; Olivieri, Ignazio ; Latanza, Loredana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-7feb94a61c846ebb907a679d06f88cd258aac9b9bb934bee6a8fc57fb356c10c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adalimumab</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Behcet Syndrome - complications</topic><topic>Behcet Syndrome - drug therapy</topic><topic>Child</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Uveitis - drug therapy</topic><topic>Uveitis - etiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Interlandi, Emanuela</creatorcontrib><creatorcontrib>Leccese, Pietro</creatorcontrib><creatorcontrib>Olivieri, Ignazio</creatorcontrib><creatorcontrib>Latanza, Loredana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Interlandi, Emanuela</au><au>Leccese, Pietro</au><au>Olivieri, Ignazio</au><au>Latanza, Loredana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>32</volume><issue>4 Suppl 84</issue><spage>S58</spage><epage>S62</epage><pages>S58-S62</pages><issn>0392-856X</issn><abstract>Behçet's disease (BD) is a chronic multisystem inflammatory disorder associated to uveitis that may represent a serious sight-threatening condition. The purpose of the present study is to assess the effectiveness of adalimumab as new strategic therapeutic approach in patients affected by severe Behçet's uveitis.
Clinical data from twelve selected patients (22 eyes) were retrospectively analysed. All patients received 40 mg of adalimumab subcutaneously, once every 2 weeks, in addition to traditional immunosuppressive on-going therapy and eight of them were switched to adalimumab after failure of infliximab therapy. Primary outcome measures included ocular inflammatory activity, frequency of uveitis attacks and steroid-sparing effect. Secondary outcomes were changes of best-corrected visual acuity (BCVA), impact on traditional immunosuppressive therapy and occurrence of adalimumab-related side effects.
Mean age of patients (11 males and 1 female) at the onset of disease was 24.34 years (±8.62 SD). Ocular involvement resulted bilateral in 83% of cases and mainly consisted in panuveitis (68% of eyes). After mean follow-up of 21 months (±9.63 SD) all patients but one (92%) achieved uveitis remission with BCVA improvement at least in one eye. Average uveitis attacks decreased from 2 to 0,42 during adalimumab (p<0.001) and daily-steroid dose was tapered in all adalimumab responders up to suspension in seven of them. No patient developed related side effects during adalimumab administration.
Our results demonstrate that adalimumab is a very effective and safe option for treatment of patients with severe and resistant Behçet's uveitis, providing an appropriate and long-term control of ocular inflammation.</abstract><cop>Italy</cop><pmid>25005224</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-856X |
| ispartof | Clinical and experimental rheumatology, 2014-07, Vol.32 (4 Suppl 84), p.S58-S62 |
| issn | 0392-856X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1567050590 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adalimumab Adolescent Adult Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Behcet Syndrome - complications Behcet Syndrome - drug therapy Child Female Follow-Up Studies Humans Male Retrospective Studies Severity of Illness Index Treatment Outcome Uveitis - drug therapy Uveitis - etiology Young Adult |
| title | Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T10%3A54%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adalimumab%20for%20treatment%20of%20severe%20Beh%C3%A7et's%20uveitis:%20a%20retrospective%20long-term%20follow-up%20study&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Interlandi,%20Emanuela&rft.date=2014-07-01&rft.volume=32&rft.issue=4%20Suppl%2084&rft.spage=S58&rft.epage=S62&rft.pages=S58-S62&rft.issn=0392-856X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1567050590%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1567050590&rft_id=info:pmid/25005224&rfr_iscdi=true |